| Document |
Document Title |
|
WO/2017/172507A1 |
The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.
|
|
WO/2017/161344A1 |
Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.
|
|
WO/2017/159484A1 |
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...
|
|
WO/2017/158388A1 |
The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubi...
|
|
WO/2017/159192A1 |
The present invention relates to: a photoelectric conversion element which has high photoelectric conversion efficiency and low dark current at the same time, while exhibiting high durability; and an optical sensor. A photoelectric conve...
|
|
WO/2017/158616A1 |
This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, ...
|
|
WO/2017/153186A1 |
The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invent...
|
|
WO/2017/155103A1 |
Provided is a novel pest control agent, particularly a pesticide or a miticide. A condensed heterocyclic compound represented by formula (1), a salt of the compound, or an N-oxide of the compound or the salt. [Q represents a structure re...
|
|
WO/2017/152972A1 |
The present invention is directed to crystalline vinorelbine monotartrate and its use for the prevention and treatment of cancer, particularly non-small cell lung cancer or breast cancer. The present invention also relates to a correspon...
|
|
WO/2017/150474A1 |
In the present invention, a composition comprising two types of thienothiophene compounds selected from the group consisting of the compounds indicated by formulas (1) to (4) (in formulas (1) to (4), either one of R1 and R2 represents an...
|
|
WO/2017/146186A1 |
Provided is a compound useful as an AMPK activator. The compound is one that is represented by formula: (in the formula, X represents a substituted or unsubstituted monocyclic heterocyclyl, etc., ring A is a substituted aryl, a substitut...
|
|
WO/2017/144633A1 |
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2017/145013A1 |
The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R 3, and R 4are as defined herein. The invention is also directed to pharmaceutical c...
|
|
WO/2017/142621A1 |
Specific cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hE...
|
|
WO/2017/140272A1 |
The present application relates to the compound of formula (I), or a pharmaceutically acceptable salt and pharmaceutical composition thereof, the compound of formula (I) or the pharmaceutically acceptable salt and pharmaceutical composit...
|
|
WO/2017/137334A1 |
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
|
|
WO/2017/133752A1 |
The invention relates to novel compounds containing one or more units derived from 2,6-disubstituted-[1,5]naphthyridine or 1,6-disubstituted-1H-[1,5]naphthyridine-2-one, to methods for their preparation and educts or intermediates used t...
|
|
WO/2017/132763A1 |
The present disclosure provides the use of a biomolecule, flavin, appended to a polymerizable unit that can then be polymerized to form an electroactive active polymer. The polymer and the flavin unit are comprised of an organic material...
|
|
WO/2017/133655A1 |
Provided are benzothiazine and benzothiadiazine and a structural analogue thereof, as well as a pharmaceutically acceptable salt, a stereoisomer and a solvate thereof, having the structure of general formula a. It has been confirmed by m...
|
|
WO/2017/125340A1 |
The invention relates to new compounds of formula (I) or (I') where R1, Aa, Ab, Ac, Ad, Q and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to met...
|
|
WO/2017/124657A1 |
Disclosed are a Bruton's tyrosine kinase inhibitor having a spiral or bridged ring structure and a preparation method thereof. The inhibitor comprises a compound of formula (I), which has the effects of inhibiting BTK activity and agains...
|
|
WO/2017/125898A1 |
The invention relates to a method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering a therapeutic agent which antagonizes or modulates the activity ...
|
|
WO/2017/121700A1 |
The invention relates to compounds of formula (I) in which Q represents a group of formula (A) or (B), R1 represents hydrogen or fluorine, and R2 represents (C1-C6)-alkyl or benzyl (wherein (C1-C6)-alkyl is substituted by a trifluorometh...
|
|
WO/2017/118252A1 |
A sulfone-containing fused heterocyclic compound and application thereof. The sulfone-containing fused heterocyclic compound is represented by formula (1), wherein L represents either an aromatic compound with a carbon number of 6 to 60 ...
|
|
WO/2017/118262A1 |
Disclosed are an organic compound and a use thereof. The organic compound has a general formula (1) as follows: wherein, -X- and -Y- respectively independently represent -O-, -S-, -S＝O-, -SO2-, -N(R100)-, -C(R200)(R201)- or -Si(R300)(R...
|
|
WO/2017/118155A1 |
The present invention relates to an organic optoelectronic material and a use thereof. The organic optoelectronic material comprises an organic compound having a characteristic structure represented by formula (1). The organic compound h...
|
|
WO/2017/115596A1 |
Provided is a heat-activated delayed-fluorescence organic electroluminescence element that has a low drive voltage, high luminous efficiency, and long life. An organic electroluminescence element that includes a luminescent layer between...
|
|
WO/2017/114843A1 |
This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.
|
|
WO/2017/114275A1 |
Disclosed is a compound represented by formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a crystal form thereof, a solvate thereof, or an isotopologue thereof. The present invention also provides a preparatio...
|
|
WO/2017/112719A1 |
The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds descr...
|
|
WO/2017/109727A1 |
The present invention relates to compounds of the general formula (I) and to a process for their preparation, to an electronic device comprising at least one of these compounds, to an emitting layer, preferably present in an electronic d...
|
|
WO/2017/112815A1 |
Specific Cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hE...
|
|
WO/2017/111176A1 |
Synthesis of an organic compound with chirality is an important technique in the fields of medicines, pesticides, health foods, etc. However, catalysts to be used for such synthesis are produced from expensive starting materials and, fur...
|
|
WO/2017/107993A1 |
A polyether compound shown in general formula 1, a use of the chelated form, hydrated form or pharmaceutically acceptable salt thereof in the preparation of a medicine, and a use of the medicine in the preparation of a medicine for treat...
|
|
WO/2017/103188A1 |
Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
|
|
WO/2017/101885A1 |
The present invention relates to a method for preparing a c-Met tyrosine kinase inhibitor, and specifically, relates to a method for preparing a mesylate crystalline form III of a compound represented by formula (I), namely 9-((8-fluoro-...
|
|
WO/2017/101763A1 |
Compounds of Formula (I) are shown below, and their pharmaceutically acceptable salts, hydrates, or solvates thereof. It involves pharmaceutical compositions of these compounds, their preparation, and their utilities in treating diseases...
|
|
WO/2017/104283A1 |
Provided are: a near-infrared absorbent composition with which a membrane having excellent infrared shielding properties and visible transparency can be produced; a membrane; an infrared cut filter; a solid-state imaging element; an infr...
|
|
WO/2017/101538A1 |
Provided are an epoxy resin composition and a prepreg, laminated board and printed-circuit board comprising same. The epoxy resin composition comprises the following components: (A) 38-54 parts by weight of an epoxy resin comprising a DC...
|
|
WO/2017/097234A1 |
The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositi...
|
|
WO/2017/100662A1 |
The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).
|
|
WO/2017/097671A1 |
The invention relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for producing same, to the use thereof alone or in combination for the treatment and/or preventio...
|
|
WO/2017/096163A1 |
Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
|
|
WO/2017/092083A1 |
Disclosed are a DPP-4 inhibitor compound, a polymer and a preparation method and use. The structure of said compound is X-R1-R2-Y, X and Y respectively being a group formed of a DPP-4 inhibitor or a DPP-4 inhibitor analogue containing an...
|
|
WO/2017/090719A1 |
Provided is a compound having an inhibitory effect on androgen receptors. A condensed pyrimidine compound represented by general formula (I) or a pharmacologically acceptable salt thereof (in the formula, X, Y, Z, R1, and R2 are as defin...
|
|
WO/2017/088289A1 |
The present invention relates to a novel compound being a JAK inhibitor. The compound is a compound of formula (I), its pharmaceutically acceptable salt, prodrug, metabolite, isotope derivative, and solvate, or a pharmaceutical compositi...
|
|
WO/2017/088790A1 |
The present invention belongs to the field of drug crystals, relates to crystals of thiadiazole derivative DPP-IV inhibitors, and in particular relates to A and B type crystals of the compound as shown in formula 7. The crystals of the p...
|
|
WO/2017/085484A1 |
The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the ...
|
|
WO/2017/081483A1 |
The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions contai...
|
|
WO/2017/081003A1 |
The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to...
|
